Page 1

1/29/26 , 5:30 PM Document EX - 99.1 2 a20210630ex991 earningsrele.htm EX - 99.1 endo Exhibit 99.1 ENDO REPORTS SECOND - QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE DUBLIN , August 5 , 2021 -- Endo International plc ( NASDAQ : ENDP ) today reported financial results for the second - quarter ended June 30 , 2021 . " Our second - quarter 2021 results reflect strong sequential growth in our Branded Pharmaceuticals segment driven by XIAFLEX® , and better than expected performance of our Sterile Injectables and Generic Pharmaceuticals segments , " said Blaise Coleman , President and Chief Executive Officer at Endo . " Moving forward , we remain committed to further advancing our strategic priorities by delivering on our business transformation initiatives and investing in the on - going launch of QWO® , the growth of XIAFLEX® and the progression of our product pipeline . " SECOND - QUARTER FINANCIAL PERFORMANCE ( in thousands , except per share amounts ) Three Months Ended June 30 , 2021 2020 Change Six Months Ended June 30 , 2021 2020 Change Total Revenues , Net $ 713,830 $ 687,588 4 % $ 1,431,749 $ 1,507,993 ( 5 ) % Reported ( Loss ) Income from Continuing Operations $ ( 10,184 ) $ Reported Diluted Weighted Average Shares 233,331 17,610 233,681 NM $ % 36,875 $ 237,043 175,191 ( 79 ) % 233,348 2 % Reported Diluted Net ( Loss ) Income per Share from Continuing Operations $ ( 0.04 ) $ 0.08 NM $ 0.16 $ 0.75 ( 79 ) % Reported Net ( Loss ) Income $ ( 15,500 ) $ 10,558 NM $ 26,024 $ 140,488 ( 81 ) % Adjusted Income from Continuing Operations ( 2 ) $ 152,121 $ 151,700 - % $ 327,038 $ 372,100 ( 12 ) % Adjusted Diluted Weighted Average Shares ( 1 ) ( 2 ) 235,416 233,681 1 % 237,043 233,348 2 % Adjusted Diluted Net Income per Share from Continuing Operations ( 2 ) $ Adjusted EBITDA ( 2 ) $ 0.65 $ 342,700 $ 0.65 336,481 - % $ 2 % $ 1.38 $ 707,415 $ 1.59 ( 13 ) % 757,607 ( 7 ) % ( 1 ) Reported Diluted Net ( Loss ) Income per Share from Continuing Operations is computed based on weighted average shares outstanding and , if there is income from continuing operations during the period , the dilutive impact of ordinary share equivalents outstanding during the period . In the case of Adjusted Diluted Weighted Average Shares , Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact . ( 2 ) The information presented in the table above includes non - GAAP financial measures such as " Adjusted Income from Continuing Operations , " " Adjusted Diluted Weighted Average Shares , " " Adjusted Diluted Net Income per Share from Continuing Operations " and " Adjusted EBITDA . " Refer to the " Supplemental Financial Information " section below for reconciliations of certain non- GAAP financial measures to the most directly comparable GAAP financial measures . CONSOLIDATED RESULTS Total revenues were $ 714 million in second - quarter 2021 , an increase of 4 % compared to $ 688 million during the same period in 2020 . This result was primarily attributable to increased revenues from the Specialty Products portfolio of our Branded Pharmaceuticals segment , partially offset by decreased revenues from our Generic Pharmaceuticals and Sterile Injectables segments . 1 https://www.sec.gov/Archives/edgar/data/1593034/000159303421000086/a20210630ex991 earningsrele.htm 1/18